Home Clinical efficacy and safety of tripterygium glycosides in treatment of stage IV diabetic nephropathy: A meta-analysis
Article Open Access

Clinical efficacy and safety of tripterygium glycosides in treatment of stage IV diabetic nephropathy: A meta-analysis

  • Yan Hong , Zhihong Gui , Xiaoping Cai and Lejian lan EMAIL logo
Published/Copyright: December 30, 2016
Download Article (PDF)
Open Medicine
From the journal Open Medicine Volume 11 Issue 1

Abstract

The aim of this meta-analysis was to evaluate the clinical efficacy and safety of tripterygium glycosides in treatment of stage IV diabetic nephropathy. Methods Through searching the PubMed and CNKI databases, the open published clinically controlled trials related to efficacy and safety of tripterygium glycosides in the treatment of stage IV diabetic nephropathy were collected. The pooled total efficacy, 24h urinary protein, serum creatinine and tripterygium glycosides related toxicity were calculated using Stata 11.0 software. Results Fourteen publications including 992 subjects (512 in the experimental group and 480 in the control group) were included in this study. Eight studies reported the total clinical efficacy comparing the experiment and control groups. No significant statistical heterogeneity was found in total efficacy (I2=24.9%, p>0.05). Thus, the combined odds ratio (OR) was pooled by fixed effect model. The pooled OR=4.16 with its 95% CI 2.71~6.37 (p<0.05), which indicated the total efficacy in the experiment group, was significant higher than that of control group (p<0.05); Thirteen studies reported the post-treatment 24h urinary protein value. Statistical heterogeneity analysis indicated significant heterogeneity across studies (I2=91.1%, p<0.05); that data was pooled by a random effects model. The combined standardized mean difference (SMD) was -1.55 with its 95% I -2.06~1.03, (p<0.05). The results indicated that post-treatment 24h urinary protein in the experiment group was significant lower than that in control group (p<0.05); Ten studies reported the post-treatment serum creatinine. Significant heterogeneity existed across those studies (I2=82.3%, p<0.05). Thereafter, the data was pooled by a random effect model. The combined standardized mean difference (SMD) was −0.24 with its 95%CI −0.40~0.09, (p<0.05). The results indicated that the post-treatment serum creatinine in experiment group was significant lower than that of control group (p<0.05); Eight studies reported tripterygium glycoside-associated toxicity such as liver function damage, gastrointestinal reactions and menstrual disorders. With no statistical heterogeneity among the studies, the data was pooled by fixed effect model. The pooled OR=6.42 (95%CI 2.23~18.48, p<0.05). The pooled results showed the tripterygium glycoside- associated toxicity incidence rate was significant higher in the experiment group than that of the control group (p<0.05); There were no publication bias for effect size of total efficacy, 24h urinary protein, and serum creatinine. However, for tripterygium glycoside-related toxicity, the publication bias was significant (t=-3.55, p<0.05). Conclusion The present evidence shows that tripterygium glycosides can improve clinical efficacy, reduce the 24h urinary protein and serum creatinine, but that they increase the tripterygium glycoside-related toxicity in treatment of stage IV diabetic nephropathy.

Keywords: Tripterygium glycosides; Clinical efficacy; Safety; Diabetic nephropathy; Meta-analysis

1 Introduction

Diabetic nephropathy (DN) is one of the most frequently diagnosed chronic complications in patients with diabetes mellitus. DN is characterized by nephrotic syndromes and diffuse scarring of the glomeruli due to longstanding diabetes mellitus and is a prime reason for dialysis in many developed countries. Published studies have confirmed that persistent proteinuria was an independent risk factor for the progression of diabetic nephropathy [1, 2] and that it was also one of the independent important prognostic factors. Therefor, reducing persistent proteinuria has become an important treatment purpose. Many clinical trials have confirmed that the renin angiotensin system and angiotensin II receptor blockers can reduce the levels of urinary protein in patients with DN, thereby delaying its progression. However, only use of angiotensin converting enzyme inhibitor/angiotensin receptor blockers (ARB/ACEI) for treatment of DN was not ideal [3,4]. Several studies [3-5] have achieved relatively go results for ARB/ACEI combined with tripterygium glycosides in the treatment of DN. However, because a small number of cases were included in each study, the statistical power was limited. Therefore, in this present meta-analysis, we included the openly available published studies and pooled the results to further evaluate the clinical efficacy and safety of tripterygium glycosides in treatment of stage IV diabetic nephropathy.

2 Methods

2.1 Publication searching

The associated publication searching procedure was performed by two reviewers independently. Clinical controlled trials comparing tripterygium glycosides plus ARB/ACEI vs. ARB/ACEI alone in the treatment of stage IV diabetic nephropathy were electronically searched in the PubMed and CNKI databases before July 2016. We used the following formula for PubMedand CNKI databases :: (“tripterygium glycosides” OR tripterygium*) AND (“diabetic nephropathy” OR DN) AND (“clinical efficacy” OR efficacy OR “urinary protein” OR “serum creatinine” OR “liver function damage” OR “gastrointestinal reaction” OR “menstrual disorders”) Searches were limited to human trials, with the language restriction of English and Chinese. All references of relevant articles were scanned for additional analysis.

2.2 Inclusion and exclusion criteria

The patients’ inclusion criteria, treatment process, and outcomes of the relevant studies were extracted by two reviewers and then checked by a third reviewer. The patients of the original studies were diagnosed of DN at clinical stage IV; the treatment drug was ACEI/ARB alone or ACEI/ARB plus tripterygium glycosides; The outcomes were restricted to total efficacy, 24h urinary protein, serum creatinine, and tripterygium glycoside-related toxicity. The exclusion criterias were: case report or review study type; duplicated publications; insufficient data for calculating OR and 95% CI; published in other languages (not Chinese or English).

2.3 Data extraction and quality assessment

Data of each included study was extracted by Lan Lejian and Hong Yan independently and cross checked. If disagreement was encountered, the third author (Zhihong Gui) was consulted for consensus. The general information such as journal where the paper was published, the authors of the paper, the year of publication and the treatment methods were extracted from each of the included papers. The results for total efficacy, 24h urinary protein, serum creatinine, and tripterygium glycoside-related toxicity were extracted by two reviewers independently and cross-checked. The methodological qualities of each included study were evaluated by two reviewers by the Cochrane Reviews Handbook standards.

2.4 Statistical analysis

We use Stata 11.0 (http://www.stata.com; Stata Corporation, College Station, TX) to do all statistical analyses. Dichotomous data was presented as odds ratio (OR) and its corresponding 95% confidence interval (CI). The measurement data was presented as standard mean difference (SMD). Statistical heterogeneity across the studies was evaluated by the chi-square (χ2) test[6], and inconsistency was calculated by I2[7]. If significant statistical heterogeneity existed among the studies (p<0.05), the random-effects method was used to pool the data. Otherwise, a fixed-effect method was used. The publication bias was evaluated by Egger’s line regression tests and Begg’s funnel plot [13].

3 Results

3.1 Publication characteristics

Two hundred and eleven publications were initially identified through searching the CNKI and PubMed databases. After reading the title, abstract, and full text,197 studies were excluded from this meta-analysis for duplicated publication, without appropriate outcome data. or not being a clinically controlled trial. Finally,14 studies with 992 subjects (512 in the experiment group and 480 in control group) were included in this study (Figure 1). The main characteristics of the included 14 publications [3-5, 8-17] are shown in Table 1.

Figure 1 The publication searching flow chart.
Figure 1

The publication searching flow chart.

Table 1

Main characteristics of the 14 studies

Studyno. ExperimentControlTreatmentCourse(month)OutcomeUrine protein
Cai 2012[8]3229TG 20mg tid+Valsartan 40-80mg/d3[(1)], [(3)]>3.5g
Huang 2010[9]2523TG 20mg tid+ Irbesartan 75-150mg/d6[(1)], [(2)], [(3)]>3.5g
Wang 2012[10]3819TG 20mg tid+Valsartan 160mg/d6[(1)], [(3)]>1.0g
Tan 2010[11]2523TG 20mg tid+ Irbesartan 75-150mg/d6[(1)], [(2)], [(3)]>3.5g
Song 2005[12]3532TG1mg/kg/d+ Benazepril 5-10mg/d6[(1)], [(3)]>1.0g
Li 2014[13]2627TG1mg/kg/d+Valsartan 80-160mg/d3[(1)], [(3)]>3.5g
Yun 2014[14]3229TG 20mg tid+Valsartan 80-160mg/d3[(1)], [(3)]>3.5g
Li 2013[15]4343TG 20mg tid+Valsartan 80mg/d3[(3)]>0.5g
Li 2013[16]3030TG1mg/kg/d+Valsartan 100mg/d3[(1)], [(2)], [(3)]>0.5g
Zha0 2011[17]2323TG 20mg tid+Valsartan 160mg/d1[(1)], [(3)]>1.5g
Chen 2013[3]2020TG1mg/kg/d+ Benazepril 20mg/d1[(1)], [(2)]>1.5g
Pu 2013[4]9898TG 20mg tid+Valsartan 80-160mg/d1[(1)], [(2)]>0.5g
Xu 2014[5]2525TG1mg/kg/d+ Benazepril 20mg/d1[(1)], [(2)], [(3)]>1.5g
Chen 2009[18]6059TG1mg/kg/d6[(1)], [(3)]>1.5g

3.2 Study quality assessment

The methodological quality of the included each study was evaluated by a six-question instrument. The general qualities of 14 studies were relative poor. Nine studies reported the adequate sequence generation. None of the included studies reported the allocation concealment, were free of selective reporting, of free of other bias. Only one study reported blindness. The outcome of methodological quality of the included 14 studies is shown in Figure 2.

Figure 2 Quality assessment. (The authors, judgments for each risk of bias item. + indicates low risk, - high risk, ? moderate risk.
Figure 2

Quality assessment. (The authors, judgments for each risk of bias item. + indicates low risk, - high risk, ? moderate risk.

3.3 Meta-analysis

3.3.1 Total efficacy

Eight studies reported the total clinical efficacy between the experiment and control groups. No significant statistical heterogeneity was found in total efficacy (I2=24.9%, p>0.05). Thus, the combined odds ratio (OR)was pooled by a fixed effect model. The pooled OR=4.16 with its 95%CI 2.71~6.37 (p<0.05), which indicated the total efficacy of the experiment group was significant higher than that of the control group (p < 0.05), Figure 3.

Figure 3 Forest plot of clinical efficacy for tripterygium glycosides in treatment of stage IV diabetic nephropathy. (The squaresand horizontal lines demonstrate the study-specific OR and 95% CI. The area of the squares reflects the stud-specific weight (inverse of the variance). The diamond represents the pooled OR and 95% CI).
Figure 3

Forest plot of clinical efficacy for tripterygium glycosides in treatment of stage IV diabetic nephropathy. (The squaresand horizontal lines demonstrate the study-specific OR and 95% CI. The area of the squares reflects the stud-specific weight (inverse of the variance). The diamond represents the pooled OR and 95% CI).

3.3.2 24h urinary protein

Thirteen studies reported the post-treatment 24h urinary protein quantity. Statistical heterogeneity analysis indicated significant heterogeneity across the studies (I2=91.1%, p<0.05). The data was pooled by a random effect model. The combined standardized mean difference (SMD) was -1.55 with its 95%CI -2.06~1.03, (p < 0.05). The results indicated that the 24h urinary protein in the experiment group was significant lower than that of the control group (p < 0.05), Figure 4.

Figure 4 Forest plot of 24h urinary protein for tripterygium glycosides in treatment of stage IV diabetic nephropathy. (The squares and horizontal lines demonstrate the study-specific OR and 95% CI. The area of the squares reflects the study specific weight (inverse of the variance). The diamond represents the pooled OR and 95% CI).
Figure 4

Forest plot of 24h urinary protein for tripterygium glycosides in treatment of stage IV diabetic nephropathy. (The squares and horizontal lines demonstrate the study-specific OR and 95% CI. The area of the squares reflects the study specific weight (inverse of the variance). The diamond represents the pooled OR and 95% CI).

3.3.3 Serum creatinine

Ten studies reported the post-treatment serum creatinine. Significant heterogeneity across the studies existed; it was evaluated by chi-square test (I2 = 82.3%, p<0.05). Thereafter, the data was pooled by a random effect model. The combined standardized mean difference (SMD) was -0.24 with its 95%CI -0.40<0.09, (p<0.05). The results indicated that after the treatment, serum creatinine in that experiment group was significant lower than that of the control group (p<0.05), Figure 5.

Figure 5 Forest plot of serum creatinine for tripterygium glycosides in treatment of stage IV diabetic nephropathy. (The squares and horizontal lines demonstrate the study-specific OR and 95% CI. The area of the squares reflects the study specific weight (inverse of the variance). The diamond represents the pooled OR and 95% CI).
Figure 5

Forest plot of serum creatinine for tripterygium glycosides in treatment of stage IV diabetic nephropathy. (The squares and horizontal lines demonstrate the study-specific OR and 95% CI. The area of the squares reflects the study specific weight (inverse of the variance). The diamond represents the pooled OR and 95% CI).

3.4 Toxicity

Eight studies reported tripterygium glycoside-associated toxicity such liver function damage, gastrointestinal reaction, or menstrual disorders. Without statistical heterogeneity among the studies, the data was pooled by a fixed effect model. The pooled OR=6.42 (95%CI: 2.23~18.48, p<0.05). The pooled results showed the tripterygium glycoside-associated toxicity incidence was significant higher than that of the control group (p<0.05), Figure 6.

Figure 6 Forest plot of tripterygium glycoside-related toxicity for tripterygium glycosides in treatment of stage IV diabetic nephropathy. (The squares and horizontal lines demonstrate the study-specific OR and 95% CI. The area of the squares reflects the study specific weight (inverse of the variance). The diamond represents the pooled OR and 95% CI).
Figure 6

Forest plot of tripterygium glycoside-related toxicity for tripterygium glycosides in treatment of stage IV diabetic nephropathy. (The squares and horizontal lines demonstrate the study-specific OR and 95% CI. The area of the squares reflects the study specific weight (inverse of the variance). The diamond represents the pooled OR and 95% CI).

3.5 Publication bias

Publication bias was evaluated by Begg’s funnel plot and Egger’s line regression test for each effect size (total efficacy, 24h urinary protein, serum creatinine, and tripterygium glycoside-related toxicity). The Begg’s funnel plot for the effect size appears asymmetric at the bottom (Figure 7). However, the Egger’s line regression test indicated no publication bias for effect size of total efficacy, 24h urinary protein, and serum creatinine. However, for tripterygium glycoside-related toxicity, the publication bias was significant (t=-3.55, p<0.05).

Figure 7 Funnel plot for evaluation the publication bias.(A: total efficacy; B: 24h urinary protein; C: serum creatinine; D: tripterygium glycosides related toxicity)
Figure 7

Funnel plot for evaluation the publication bias.(A: total efficacy; B: 24h urinary protein; C: serum creatinine; D: tripterygium glycosides related toxicity)

4 Discussion

Diabetic nephropathy, also known as diabetic kidney disease, is a progressive kidney disease caused by damage to the capillaries in the kidneys’ glomeruli [19].The pathogenesis of diabetic nephropathy includes many factors such as hemodynamics, inflammation, oxidative stress, and immune reactions [20-22]. The clinical symptom of diabetic nephropathy is proteinuria, and renal function gradually decreases. The purposes for treatment for DN were to decrease the progression of kidney damage and control associated complications such as proteinuria, hypoproteinemia, and others. The major treatment modality was angiotensin converting enzyme inhibitor / angiotensin receptor blockers (ARB/ACEI)[23, 24]. This treatment can generally reduce proteinuria and retard the progression of DN. Other factors such as controlling high blood pressure, controlling blood sugar levels, and dietary salt intake are also important for the DN management.

Recently, several prospective clinical studies have discussed the clinical efficacy of tripterygium glycosides in treatment of stage IV diabetic nephropathy. Most of the studies showed that ARB/ACEI combined with tripterygium glycosides can improve clinical efficacy, decrease the 24h urinary protein, and serum creatinine. However, the indicators of tripterygium glycoside-associated toxicity, such as nausea and vomiting, anorexia, abdominal distension, and bone marrow suppression was also increased. However, because a small number of cases was included in each study, the statistical power was limited. To further investigate the clinical efficacy and safety of tripterygium glycosides in treatment of stage IV diabetic nephropathy, studies must be performed with larger study groups. In our present meta-analysis,14 prospective clinical studies including 992 subjects (512 in experiment group and 480 in congrol group) were included. Eight studies reported the total clinical efficacy between experiment and control groups. The pooled results indicated the total efficacy of the experiment group was significant higher than that of the control group (p<0.05). This result demonstrated that ARB/ACEI combined with tripterygium glycosides can improve the clinical efficacy by about 4-fold. Thirteen studies reported the post-treatment 24h urinary protein quantity; the combined standardized mean difference (SMD) was -1.55. That result indicated that the after treatment, the 24h urinary protein in the experiment group was significant lower than that of the control group (p<0.05), showing that ARB/ACEI combined with tripterygium glycosides can significant decrease the 24h urinary protein compared with ARB/ACEI use alone. Ten studies reported the post-treatment serum creatinine. The results indicated that the after treatment, ARB/ACEI combined with tripterygium glycosides can significantly decrease the serum creatinine compared with ARB/ACEI only (p<0.05); Eight studies reported tripterygium glycoside-associated toxicity such as liver function damage, gastrointestinal reaction, and menstrual disorders. The pooled results showed the tripterygium glycoside-associated toxicity incidence was significant higher than that of the control group (p<0.05). Thus, the present evidence indicates that tripterygium glycosides combined with ARB/ACEI can improve clinical efficacy, reduce the 24h urinary protein, and serum creatinine as compared with ARB/ACEI treatment only.

Several limitations were also found in this meta-analysis: (1) The general quality of the included studies was poor; (2) Significant statistical heterogeneity existed across the included studies; (3) Only Chinese and English studies were included in this meta-analysis; (4) Significant publication bias was found in this meta-analysis.

Tel. +86-(0578)2780013

  1. Conflict of interest statement: Authors state no conflict of interest.

References

[1] Tziomalos K, Athyros VG. Diabetic Nephropathy: New Risk Factors and Improvements in Diagnosis. Rev Diabet Stud 2015;12:110-11810.1900/RDS.2015.12.110Search in Google Scholar

[2] Svensson MK, Tyrberg M, Nystrom L, et al. The risk for diabetic nephropathy is low in young adults in a 17-year follow-up from the Diabetes Incidence Study in Sweden (DISS). Older age and higher BMI at diabetes onset can be important risk factors. Diabetes Metab Res Rev 2015;31:138-14610.1002/dmrr.2574Search in Google Scholar

[3] Chen XY. Clinical observation of benazepril combined with tripterygium glycosides in the treatment of diabetic nephropathy. Shaanxi Journal of Traditional Chinese Medicine 2013;34:1016-1017Search in Google Scholar

[4] Pu Y, Zou QM, Pu W. Analysis of the effect of Valsartan combined with tripterygium glycosides in the treatment of diabetic nephropathy. Jilin Medical Journal 2013;34:5789-5791Search in Google Scholar

[5] Xu BX. Clinical analysis of tripterygium glycosides combined with benazepril in the treatment of diabetic nephropathy. Journal of Bethune Military Medical College 2014;12:90-91Search in Google Scholar

[6] DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-18810.1016/0197-2456(86)90046-2Search in Google Scholar

[7] Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-56010.1136/bmj.327.7414.557Search in Google Scholar PubMed PubMed Central

[8] Cai XP. ARB combined with tripterygium glycosides in the treatment of diabetic nephropathy. Journal of Clinical Medicine in Practice 2012;16:112-114Search in Google Scholar

[9] Huang NC. Clinical study of tripterygium glycosides and irbesartan in the treatment of diabetic nephropathy. Jilin Medical Journal 2010;31:5312-5313Search in Google Scholar

[10] Wang ML. Clinical observation on the effect of valsartan combined with tripterygium glycosides in the treatment of diabetic nephropathy. Chinese Journal of Clinical Rational Drug Use 2012;5:84-85Search in Google Scholar

[11] Tan YS, Wang M. Tripterygium glycosides combined irbesartan in the treatment of diabetic nephropathy. China Healthcare Innovation 2010:32-33Search in Google Scholar

[12] Song HX Gong J, Chen W, et al. Effects of tripterygium glycosides on urinary monocyte chemotaxis protein -1 in diabetic nephropathy patients. Chinese Journal of Integrated Traditional and Western Medicine 2005;5:416-418Search in Google Scholar

[13] Li D. Tripterygium glycosides adjuvant treatment of diabetic nephropathy: reported of 53 cases. Heilongjiang Medical Journal 2014;38:1029-1030Search in Google Scholar

[14] Yu WF. A clincial study of tripterygium glycosides adjuvant treatment of diabetic nephropathy. Nei Mongol Journal of Traditional Chinese Medicine 2014;26:15Search in Google Scholar

[15] Li MR. Clinical study of Tripterygium glycosides combined with valsartan capsule in treatment of diabetic nephropathy. 2013;9:138Search in Google Scholar

[16] Li H. Efficacy and safety of tripterygium glycosides combined with losartan in the treatment of diabetic nephropathy. Chinese Remedies & Clinics 2013;13:649-650Search in Google Scholar

[17] Zhao RY, Tang BS, Shi XL, et al. Clinical effect of tripterygium glycosides combined with observation in the treatment of diabetic nephropathy: reported of 46 cases. Chinese Journal of Integrated Traditional and Western Nephrology 2011;12:811-813Search in Google Scholar

[18] Chen QN. Clinical observation of tripterygium glycosides int treatment of diabetic nephropathy. Chinese Journal of Integrated Traditional and Western Nephrology 2009;10:717-718Search in Google Scholar

[19] Ringholm L, Damm JA, Vestgaard M, et al. Diabetic Nephropathy in Women With Preexisting Diabetes: From Pregnancy Planning to Breastfeeding. Curr Diab Rep 2016;16:1210.1007/s11892-015-0705-3Search in Google Scholar PubMed

[20] Marketou NP, Auid Oho, Chrousos GP, et al. Diabetic Nephropathy in Type 1 Diabetes: A Review of Early Natural History, Pathogenesis and Diagnosis. Diabetes Metab Res Rev 2016Search in Google Scholar

[21] Kume S, Koya D, Uzu T, et al. Role of nutrient-sensing signals in the pathogenesis of diabetic nephropathy. Biomed Res Int 2014;2014:31549410.1155/2014/315494Search in Google Scholar PubMed PubMed Central

[22] Yamahara K, Yasuda M, Kume S, et al. The role of autophagy in the pathogenesis of diabetic nephropathy. Journal of diabetes research 2013;2013:19375710.1155/2013/193757Search in Google Scholar PubMed PubMed Central

[23] Abdelhafiz AH, Nahas ME, de Oliveira JM. Management of diabetic nephropathy in older patients: a need for flexible guidelines. Postgrad Med 2014;126:171-17710.3810/pgm.2014.07.2794Search in Google Scholar PubMed

[24] [24] Chan G, Tang SC. Current practices in the management of diabetic nephropathy. J R Coll Physicians Edinb 2013;43:330-33210.4997/JRCPE.2013.413Search in Google Scholar PubMed

Received: 2016-10-29
Accepted: 2016-12-16
Published Online: 2016-12-30
Published in Print: 2016-1-1

© 2016 Yan Hong et al.

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Articles in the same Issue

  1. Research Article
  2. The possible molecular regulation mechanism of CIK cells inhibiting the proliferation of Human Lung Adenocarcinoma NCL-H157 Cells
  3. Case Report
  4. Urethral stone of unexpected size: case report and short literature review
  5. Case Report
  6. Complete remission through icotinib treatment in Non-small cell lung cancer epidermal growth factor receptor mutation patient with brain metastasis: A case report
  7. Research Article
  8. FPL tendon thickness, tremor and hand functions in Parkinson’s disease
  9. Research Article
  10. Diagnostic value of circulating tumor cells in cerebrospinal fluid
  11. Research Article
  12. A meta-analysis of neuroprotective effect for traditional Chinese medicine (TCM) in the treatment of glaucoma
  13. Research Article
  14. MiR-218 increases sensitivity to cisplatin in esophageal cancer cells via targeting survivin expression
  15. Research Article
  16. Association of HOTAIR expression with PI3K/Akt pathway activation in adenocarcinoma of esophagogastric junction
  17. Research Article
  18. The role of interleukin genes in the course of depression
  19. Case Report
  20. A rare case of primary pulmonary diffuse large B cell lymphoma with CD5 positive expression
  21. Research Article
  22. DWI and SPARCC scoring assess curative effect of early ankylosing spondylitis
  23. Research Article
  24. The diagnostic value of serum CEA, NSE and MMP-9 for on-small cell lung cancer
  25. Case Report
  26. Dysphonia – the single symptom of rifampicin resistant laryngeal tuberculosis
  27. Review Article
  28. Development of epidermal growth factor receptor tyrosine kinase inhibitors against EGFR T790M. Mutation in non small-cell lung carcinoma
  29. Research Article
  30. Negative regulation of CDC42 expression and cell cycle progression by miR-29a in breast cancer
  31. Research Article
  32. Expression analysis of the TGF-β/SMAD target genes in adenocarcinoma of esophagogastric junction
  33. Research Article
  34. Blood cells in thyroid cancer patients: a possible influence of apoptosis
  35. Research Article
  36. Detected EGFR mutation in cerebrospinal fluid of lung adenocarcinoma patients with meningeal metastasis
  37. Mini-review
  38. Pathogenesis-oriented approaches for the management of corticosteroid-resistant or relapsedprimary immune thrombocytopenia
  39. Research Article
  40. GSTP1 A>G polymorphism and chemosensitivity of osteosarcoma: A meta-analysis
  41. Research Article
  42. A meta-analysis of adiponectin gene rs22411766 T>G polymorphism and ischemic stroke susceptibility
  43. Research Article
  44. The diagnosis and pathological value of combined detection of HE4 and CA125 for patients with ovarian cancer
  45. Research Article
  46. SOX7 inhibits tumor progression of glioblastoma and is regulated by miRNA-24
  47. Research Article
  48. Sevoflurane affects evoked electromyography monitoring in cerebral palsy
  49. Case Report
  50. A case report of hereditary spherocytosis with concomitant chronic myelocytic leukemia
  51. Case Report
  52. A case of giant saphenous vein graft aneurysm followed serially after coronary artery bypass surgery
  53. Research Article
  54. LncRNA TUG1 is upregulated and promotes cell proliferation in osteosarcoma
  55. Review Article
  56. Meningioma recurrence
  57. Case Report
  58. Endobronchial amyloidosis mimicking bronchial asthma: a case report and review of the literature
  59. Case Report
  60. A confusing case report of pulmonary langerhans cell histiocytosis and literature review
  61. Research Article
  62. Effect of hesperetin on chaperone activity in selenite-induced cataract
  63. Research Article
  64. Clinical value of self-assessment risk of osteoporosis in Chinese
  65. Research Article
  66. Correlation analysis of VHL and Jade-1 gene expression in human renal cell carcinoma
  67. Research Article
  68. Is acute appendicitis still misdiagnosed?
  69. Retraction
  70. Retraction of: application of food-specific IgG antibody detection in allergy dermatosis
  71. Review Article
  72. Platelet Rich Plasma: a short overview of certain bioactive components
  73. Research Article
  74. Correlation between CTLA-4 gene rs221775A>G single nucleotide polymorphism and multiple sclerosis susceptibility. A meta-analysis
  75. Review Article
  76. Standards of anesthesiology practice during neuroradiological interventions
  77. Research Article
  78. Expression and clinical significance of LXRα and SREBP-1c in placentas of preeclampsia
  79. Letter to the Editor
  80. ARDS diagnosed by SpO2/FiO2 ratio compared with PaO2/FiO2 ratio: the role as a diagnostic tool for early enrolment into clinical trials
  81. Research Article
  82. Impact of sensory integration training on balance among stroke patients: sensory integration training on balance among stroke patients
  83. Review Article
  84. MicroRNAs as regulatory elements in psoriasis
  85. Review Article
  86. Influenza A(H1N1)pdm09 and postpandemic influenza in Lithuania
  87. Review Article
  88. Garengeot’s hernia: two case reports with CT diagnosis and literature review
  89. Research Article
  90. Concept of experimental preparation for treating dentin hypersensitivity
  91. Research Article
  92. Hydrogen water reduces NSE, IL-6, and TNF-α levels in hypoxic-ischemic encephalopathy
  93. Research Article
  94. Xanthogranuloma of the sellar region diagnosed by frozen section
  95. Case Report
  96. Laparoscopic antegrade cholecystectomy: a standard procedure?
  97. Case Report
  98. Maxillary fibrous dysplasia associated with McCune-Albright syndrome. A case study
  99. Regular Article
  100. Sialoendoscopy, sialography, and ultrasound: a comparison of diagnostic methods
  101. Research Article
  102. Antibody Response to Live Attenuated Vaccines in Adults in Japan
  103. Conference article
  104. Excellence and safety in surgery require excellent and safe tutoring
  105. Conference article
  106. Suggestions on how to make suboptimal kidney transplantation an ethically viable option
  107. Regular Article
  108. Ectopic pregnancy treatment by combination therapy
  109. Conference article
  110. Use of a simplified consent form to facilitate patient understanding of informed consent for laparoscopic cholecystectomy
  111. Regular Article
  112. Cusum analysis for learning curve of videothoracoscopic lobectomy
  113. Regular Article
  114. A meta-analysis of association between glutathione S-transferase M1 gene polymorphism and Parkinson’s disease susceptibility
  115. Conference article
  116. Plastination: ethical and medico-legal considerations
  117. Regular Article
  118. Investigation and control of a suspected nosocomial outbreak of pan-drug resistant Acinetobacter baumannii in an intensive care unit
  119. Regular Article
  120. Multifactorial analysis of fatigue scale among nurses in Poland
  121. Regular Article
  122. Smoking cessation for free: outcomes of a study of three Romanian clinics
  123. Regular Article
  124. Clinical efficacy and safety of tripterygium glycosides in treatment of stage IV diabetic nephropathy: A meta-analysis
  125. Special Issue on Italian Society for the Study of Vascular Anomalies
  126. Prevention and treatment of peritoneal adhesions in patients affected by vascular diseases following surgery: a review of the literature
  127. Special Issue on Italian Society for the Study of Vascular Anomalies
  128. Surgical treatment of recidivist lymphedema
  129. Special Issue on Italian Society for the Study of Vascular Anomalies
  130. CT and MR imaging of the thoracic aorta
  131. Special Issue on Italian Society for the Study of Vascular Anomalies
  132. Role of FDG-PET scan in staging of pulmonary epithelioid hemangioendothelioma
  133. Special Issue on Italian Society for the Study of Vascular Anomalies
  134. Sternal reconstruction by extracellular matrix: a rare case of phaces syndrome
  135. Special Issue on Italian Society for the Study of Vascular Anomalies
  136. Prenatal diagnosis, 3-D virtual rendering and lung sparing surgery by ligasure device in a baby with “CCAM and intralobar pulmonary sequestration”
  137. Special Issue on Italian Society for the Study of Vascular Anomalies
  138. Serum levels of inhibin B in adolescents after varicocelelectomy: A long term follow up
  139. Special Issue on Italian Society for the Study of Vascular Anomalies
  140. Our experience in the treatment of Malignant Fibrous Hystiocytoma of the larynx: clinical diagnosis, therapeutic approach and review of literature
  141. Special Issue on Italian Society for the Study of Vascular Anomalies
  142. Delayed recurrent nerve paralysis following post-traumatic aortic pseudoaneurysm
  143. Special Issue on Italian Society for the Study of Vascular Anomalies
  144. Integrated therapeutic approach to giant solitary fibrous tumor of the pleura: report of a case and review of the literature
  145. Special Issue on Italian Society for the Study of Vascular Anomalies
  146. Celiac axis compression syndrome: laparoscopic approach in a strange case of chronic abdominal pain in 71 years old man
  147. Special Issue on Italian Society for the Study of Vascular Anomalies
  148. A rare case of persistent hypoglossal artery associated with contralateral proximal subclavian stenosis
  149. Focus on Medico-Legal and Ethical Topics in Surgery in Italy
  150. Contralateral risk reducing mastectomy in Non-BRCA-Mutated patients
  151. Focus on Medico-Legal and Ethical Topics in Surgery in Italy
  152. Professional dental and oral surgery liability in Italy: a comparative analysis of the insurance products offered to health workers
  153. Focus on Medico-Legal and Ethical Topics in Surgery in Italy
  154. Informed consent in robotic surgery: quality of information and patient perception
  155. Focus on Medico-Legal and Ethical Topics in Surgery in Italy
  156. Malfunctions of robotic system in surgery: role and responsibility of surgeon in legal point of view
  157. Focus on Medico-Legal and Ethical Topics in Surgery in Italy
  158. Medicolegal implications of surgical errors and complications in neck surgery: A review based on the Italian current legislation
  159. Focus on Medico-Legal and Ethical Topics in Surgery in Italy
  160. Iatrogenic splenic injury: review of the literature and medico-legal issues
  161. Focus on Medico-Legal and Ethical Topics in Surgery in Italy
  162. Donation of the body for scientific purposes in Italy: ethical and medico-legal considerations
  163. Focus on Medico-Legal and Ethical Topics in Surgery in Italy
  164. Cosmetic surgery: medicolegal considerations
  165. Focus on Medico-Legal and Ethical Topics in Surgery in Italy
  166. Voluntary termination of pregnancy (medical or surgical abortion): forensic medicine issues
  167. Review Article
  168. Role of Laparoscopic Splenectomy in Elderly Immune Thrombocytopenia
  169. Review Article
  170. Endoscopic diagnosis and treatment of neuroendocrine tumors of the digestive system
  171. Review Article
  172. Efficacy and safety of splenectomy in adult autoimmune hemolytic anemia
  173. Research Article
  174. Relationship between gastroesophageal reflux disease and Ph nose and salivary: proposal of a simple method outpatient in patients adults
  175. Case Report
  176. Idiopathic pleural panniculitis with recurrent pleural effusion not associated with Weber-Christian disease
  177. Research Article
  178. Morbid Obesity: treatment with Bioenterics Intragastric Balloon (BIB), psychological and nursing care: our experience
  179. Research Article
  180. Learning curve for endorectal ultrasound in young and elderly: lights and shades
  181. Case Report
  182. Uncommon primary hydatid cyst occupying the adrenal gland space, treated with laparoscopic surgical approach in an old patient
  183. Research Article
  184. Distraction techniques for face and smile aesthetic preventing ageing decay
  185. Research Article
  186. Preoperative high-intensity training in frail old patients undergoing pulmonary resection for NSCLC
  187. Review Article
  188. Descending necrotizing mediastinitis in the elderly patients
  189. Research Article
  190. Prophylactic GSV surgery in elderly candidates for hip or knee arthroplasty
  191. Research Article
  192. Diagnostic yield and safety of C-TBNA in elderly patients with lung cancer
  193. Research Article
  194. The learning curve of laparoscopic holecystectomy in general surgery resident training: old age of the patient may be a risk factor?
  195. Research Article
  196. Self-gripping mesh versus fibrin glue fixation in laparoscopic inguinal hernia repair: a randomized prospective clinical trial in young and elderly patients
  197. Research Article
  198. Anal sphincter dysfunction in multiple sclerosis: an observation manometric study
https://doi.org/10.1515/med-2016-0099
Keywords for this article
Tripterygium glycosides; Clinical efficacy; Safety; Diabetic nephropathy; Meta-analysis
Creative Commons
BY-NC-ND 3.0

Articles in the same Issue

  1. Research Article
  2. The possible molecular regulation mechanism of CIK cells inhibiting the proliferation of Human Lung Adenocarcinoma NCL-H157 Cells
  3. Case Report
  4. Urethral stone of unexpected size: case report and short literature review
  5. Case Report
  6. Complete remission through icotinib treatment in Non-small cell lung cancer epidermal growth factor receptor mutation patient with brain metastasis: A case report
  7. Research Article
  8. FPL tendon thickness, tremor and hand functions in Parkinson’s disease
  9. Research Article
  10. Diagnostic value of circulating tumor cells in cerebrospinal fluid
  11. Research Article
  12. A meta-analysis of neuroprotective effect for traditional Chinese medicine (TCM) in the treatment of glaucoma
  13. Research Article
  14. MiR-218 increases sensitivity to cisplatin in esophageal cancer cells via targeting survivin expression
  15. Research Article
  16. Association of HOTAIR expression with PI3K/Akt pathway activation in adenocarcinoma of esophagogastric junction
  17. Research Article
  18. The role of interleukin genes in the course of depression
  19. Case Report
  20. A rare case of primary pulmonary diffuse large B cell lymphoma with CD5 positive expression
  21. Research Article
  22. DWI and SPARCC scoring assess curative effect of early ankylosing spondylitis
  23. Research Article
  24. The diagnostic value of serum CEA, NSE and MMP-9 for on-small cell lung cancer
  25. Case Report
  26. Dysphonia – the single symptom of rifampicin resistant laryngeal tuberculosis
  27. Review Article
  28. Development of epidermal growth factor receptor tyrosine kinase inhibitors against EGFR T790M. Mutation in non small-cell lung carcinoma
  29. Research Article
  30. Negative regulation of CDC42 expression and cell cycle progression by miR-29a in breast cancer
  31. Research Article
  32. Expression analysis of the TGF-β/SMAD target genes in adenocarcinoma of esophagogastric junction
  33. Research Article
  34. Blood cells in thyroid cancer patients: a possible influence of apoptosis
  35. Research Article
  36. Detected EGFR mutation in cerebrospinal fluid of lung adenocarcinoma patients with meningeal metastasis
  37. Mini-review
  38. Pathogenesis-oriented approaches for the management of corticosteroid-resistant or relapsedprimary immune thrombocytopenia
  39. Research Article
  40. GSTP1 A>G polymorphism and chemosensitivity of osteosarcoma: A meta-analysis
  41. Research Article
  42. A meta-analysis of adiponectin gene rs22411766 T>G polymorphism and ischemic stroke susceptibility
  43. Research Article
  44. The diagnosis and pathological value of combined detection of HE4 and CA125 for patients with ovarian cancer
  45. Research Article
  46. SOX7 inhibits tumor progression of glioblastoma and is regulated by miRNA-24
  47. Research Article
  48. Sevoflurane affects evoked electromyography monitoring in cerebral palsy
  49. Case Report
  50. A case report of hereditary spherocytosis with concomitant chronic myelocytic leukemia
  51. Case Report
  52. A case of giant saphenous vein graft aneurysm followed serially after coronary artery bypass surgery
  53. Research Article
  54. LncRNA TUG1 is upregulated and promotes cell proliferation in osteosarcoma
  55. Review Article
  56. Meningioma recurrence
  57. Case Report
  58. Endobronchial amyloidosis mimicking bronchial asthma: a case report and review of the literature
  59. Case Report
  60. A confusing case report of pulmonary langerhans cell histiocytosis and literature review
  61. Research Article
  62. Effect of hesperetin on chaperone activity in selenite-induced cataract
  63. Research Article
  64. Clinical value of self-assessment risk of osteoporosis in Chinese
  65. Research Article
  66. Correlation analysis of VHL and Jade-1 gene expression in human renal cell carcinoma
  67. Research Article
  68. Is acute appendicitis still misdiagnosed?
  69. Retraction
  70. Retraction of: application of food-specific IgG antibody detection in allergy dermatosis
  71. Review Article
  72. Platelet Rich Plasma: a short overview of certain bioactive components
  73. Research Article
  74. Correlation between CTLA-4 gene rs221775A>G single nucleotide polymorphism and multiple sclerosis susceptibility. A meta-analysis
  75. Review Article
  76. Standards of anesthesiology practice during neuroradiological interventions
  77. Research Article
  78. Expression and clinical significance of LXRα and SREBP-1c in placentas of preeclampsia
  79. Letter to the Editor
  80. ARDS diagnosed by SpO2/FiO2 ratio compared with PaO2/FiO2 ratio: the role as a diagnostic tool for early enrolment into clinical trials
  81. Research Article
  82. Impact of sensory integration training on balance among stroke patients: sensory integration training on balance among stroke patients
  83. Review Article
  84. MicroRNAs as regulatory elements in psoriasis
  85. Review Article
  86. Influenza A(H1N1)pdm09 and postpandemic influenza in Lithuania
  87. Review Article
  88. Garengeot’s hernia: two case reports with CT diagnosis and literature review
  89. Research Article
  90. Concept of experimental preparation for treating dentin hypersensitivity
  91. Research Article
  92. Hydrogen water reduces NSE, IL-6, and TNF-α levels in hypoxic-ischemic encephalopathy
  93. Research Article
  94. Xanthogranuloma of the sellar region diagnosed by frozen section
  95. Case Report
  96. Laparoscopic antegrade cholecystectomy: a standard procedure?
  97. Case Report
  98. Maxillary fibrous dysplasia associated with McCune-Albright syndrome. A case study
  99. Regular Article
  100. Sialoendoscopy, sialography, and ultrasound: a comparison of diagnostic methods
  101. Research Article
  102. Antibody Response to Live Attenuated Vaccines in Adults in Japan
  103. Conference article
  104. Excellence and safety in surgery require excellent and safe tutoring
  105. Conference article
  106. Suggestions on how to make suboptimal kidney transplantation an ethically viable option
  107. Regular Article
  108. Ectopic pregnancy treatment by combination therapy
  109. Conference article
  110. Use of a simplified consent form to facilitate patient understanding of informed consent for laparoscopic cholecystectomy
  111. Regular Article
  112. Cusum analysis for learning curve of videothoracoscopic lobectomy
  113. Regular Article
  114. A meta-analysis of association between glutathione S-transferase M1 gene polymorphism and Parkinson’s disease susceptibility
  115. Conference article
  116. Plastination: ethical and medico-legal considerations
  117. Regular Article
  118. Investigation and control of a suspected nosocomial outbreak of pan-drug resistant Acinetobacter baumannii in an intensive care unit
  119. Regular Article
  120. Multifactorial analysis of fatigue scale among nurses in Poland
  121. Regular Article
  122. Smoking cessation for free: outcomes of a study of three Romanian clinics
  123. Regular Article
  124. Clinical efficacy and safety of tripterygium glycosides in treatment of stage IV diabetic nephropathy: A meta-analysis
  125. Special Issue on Italian Society for the Study of Vascular Anomalies
  126. Prevention and treatment of peritoneal adhesions in patients affected by vascular diseases following surgery: a review of the literature
  127. Special Issue on Italian Society for the Study of Vascular Anomalies
  128. Surgical treatment of recidivist lymphedema
  129. Special Issue on Italian Society for the Study of Vascular Anomalies
  130. CT and MR imaging of the thoracic aorta
  131. Special Issue on Italian Society for the Study of Vascular Anomalies
  132. Role of FDG-PET scan in staging of pulmonary epithelioid hemangioendothelioma
  133. Special Issue on Italian Society for the Study of Vascular Anomalies
  134. Sternal reconstruction by extracellular matrix: a rare case of phaces syndrome
  135. Special Issue on Italian Society for the Study of Vascular Anomalies
  136. Prenatal diagnosis, 3-D virtual rendering and lung sparing surgery by ligasure device in a baby with “CCAM and intralobar pulmonary sequestration”
  137. Special Issue on Italian Society for the Study of Vascular Anomalies
  138. Serum levels of inhibin B in adolescents after varicocelelectomy: A long term follow up
  139. Special Issue on Italian Society for the Study of Vascular Anomalies
  140. Our experience in the treatment of Malignant Fibrous Hystiocytoma of the larynx: clinical diagnosis, therapeutic approach and review of literature
  141. Special Issue on Italian Society for the Study of Vascular Anomalies
  142. Delayed recurrent nerve paralysis following post-traumatic aortic pseudoaneurysm
  143. Special Issue on Italian Society for the Study of Vascular Anomalies
  144. Integrated therapeutic approach to giant solitary fibrous tumor of the pleura: report of a case and review of the literature
  145. Special Issue on Italian Society for the Study of Vascular Anomalies
  146. Celiac axis compression syndrome: laparoscopic approach in a strange case of chronic abdominal pain in 71 years old man
  147. Special Issue on Italian Society for the Study of Vascular Anomalies
  148. A rare case of persistent hypoglossal artery associated with contralateral proximal subclavian stenosis
  149. Focus on Medico-Legal and Ethical Topics in Surgery in Italy
  150. Contralateral risk reducing mastectomy in Non-BRCA-Mutated patients
  151. Focus on Medico-Legal and Ethical Topics in Surgery in Italy
  152. Professional dental and oral surgery liability in Italy: a comparative analysis of the insurance products offered to health workers
  153. Focus on Medico-Legal and Ethical Topics in Surgery in Italy
  154. Informed consent in robotic surgery: quality of information and patient perception
  155. Focus on Medico-Legal and Ethical Topics in Surgery in Italy
  156. Malfunctions of robotic system in surgery: role and responsibility of surgeon in legal point of view
  157. Focus on Medico-Legal and Ethical Topics in Surgery in Italy
  158. Medicolegal implications of surgical errors and complications in neck surgery: A review based on the Italian current legislation
  159. Focus on Medico-Legal and Ethical Topics in Surgery in Italy
  160. Iatrogenic splenic injury: review of the literature and medico-legal issues
  161. Focus on Medico-Legal and Ethical Topics in Surgery in Italy
  162. Donation of the body for scientific purposes in Italy: ethical and medico-legal considerations
  163. Focus on Medico-Legal and Ethical Topics in Surgery in Italy
  164. Cosmetic surgery: medicolegal considerations
  165. Focus on Medico-Legal and Ethical Topics in Surgery in Italy
  166. Voluntary termination of pregnancy (medical or surgical abortion): forensic medicine issues
  167. Review Article
  168. Role of Laparoscopic Splenectomy in Elderly Immune Thrombocytopenia
  169. Review Article
  170. Endoscopic diagnosis and treatment of neuroendocrine tumors of the digestive system
  171. Review Article
  172. Efficacy and safety of splenectomy in adult autoimmune hemolytic anemia
  173. Research Article
  174. Relationship between gastroesophageal reflux disease and Ph nose and salivary: proposal of a simple method outpatient in patients adults
  175. Case Report
  176. Idiopathic pleural panniculitis with recurrent pleural effusion not associated with Weber-Christian disease
  177. Research Article
  178. Morbid Obesity: treatment with Bioenterics Intragastric Balloon (BIB), psychological and nursing care: our experience
  179. Research Article
  180. Learning curve for endorectal ultrasound in young and elderly: lights and shades
  181. Case Report
  182. Uncommon primary hydatid cyst occupying the adrenal gland space, treated with laparoscopic surgical approach in an old patient
  183. Research Article
  184. Distraction techniques for face and smile aesthetic preventing ageing decay
  185. Research Article
  186. Preoperative high-intensity training in frail old patients undergoing pulmonary resection for NSCLC
  187. Review Article
  188. Descending necrotizing mediastinitis in the elderly patients
  189. Research Article
  190. Prophylactic GSV surgery in elderly candidates for hip or knee arthroplasty
  191. Research Article
  192. Diagnostic yield and safety of C-TBNA in elderly patients with lung cancer
  193. Research Article
  194. The learning curve of laparoscopic holecystectomy in general surgery resident training: old age of the patient may be a risk factor?
  195. Research Article
  196. Self-gripping mesh versus fibrin glue fixation in laparoscopic inguinal hernia repair: a randomized prospective clinical trial in young and elderly patients
  197. Research Article
  198. Anal sphincter dysfunction in multiple sclerosis: an observation manometric study
Sign up now to receive a 20% welcome discount
Institutional Access
How does access work?
Have an idea on how to improve our website?
Please write us.
© 2025 De Gruyter Brill
Downloaded on 1.11.2025 from https://www.degruyterbrill.com/document/doi/10.1515/med-2016-0099/html
Scroll to top button